Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 5/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | CDK7 | P50613 | 7/20 | 0.37 |
| ▸ | CCNH | P51946 | 4/20 | 0.37 |
| ▸ | CDK1 | P06493 | 3/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.37 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.37 |
| ▸ | CDK4 | P11802 | 2/20 | 0.37 |
| ▸ | CDK9 | P50750 | 2/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | GPR39 | O43194 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.35 |
| ▸ | FLT3 | P36888 | 3/20 | 0.35 |
| ▸ | NRAS | P01111 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24791683 | 0.88 | CDK2 (0.45) | CSNK2A2CDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL24791659 | 0.88 | CDK2 (0.45) | CSNK2A2CDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL24791684 | 0.88 | CDK2 (0.45) | CSNK2A2CDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL24792400 | 0.88 | CDK7 (0.50) | CSNK2A2CDK2GSK3BCDK7CCNH | |
| SCHEMBL30083488 | 0.87 | CDK7 (0.54) | CSNK2A2CDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL24792392 | 0.87 | CDK7 (0.54) | CSNK2A2CDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL30083469 | 0.84 | GPR39 (0.41) | CSNK2A2CDK2CCNA2GSK3BCDK7 | |
| SCHEMBL24791508 | 0.84 | CDK2 (0.49) | CDK2CHEK1CCNA2CCNA1GSK3B | |
| SCHEMBL24791510 | 0.84 | CDK2 (0.49) | CDK2CHEK1CCNA2CCNA1GSK3B | |
| SCHEMBL24792971 | 0.83 | CDK2 (0.47) | CSNK2A2CDK2CHEK1CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383900-A1 | SUBSTITUTED PYRAZOLO [1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2024-11-21 | — | — | US | disclosed |
| CN-117940427-A | Substituted pyrazolo [1,5-a ] pyrimidine-7-amine compounds as CDK inhibitors and therapeutic uses thereof | 卡里克治疗有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4355426-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2024-04-24 | — | — | EP | disclosed |
| WO-2022263604-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022263604-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383900-A1 | SUBSTITUTED PYRAZOLO [1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CDK3, CDK1, CDK2 | CSNK2A2 252/4885CDK2 3/4885CHEK1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.